Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.

Marie VialaMarie AlexandreSimon ThezenasPierre-Jean LamyAurélie Maran-GonzalezMarian GutowskiPierre-Emmanuel ColomboGilles RomieuWilliam JacotSeverine Guiu

Published in: Breast cancer research and treatment (2017)

The personalization of the patients' treatment using uPA/PAI-1 tumor levels allows the reversion of the well-known poor prognostic impact of high uPA/PAI-1 levels and strongly supports the use of this biomarker in clinical practice.

Keyphrases

clinical practice
end stage renal disease
newly diagnosed
ejection fraction
early stage
chronic kidney disease
breast cancer cells
estrogen receptor
smoking cessation